Results 21 to 30 of about 1,759,507 (251)

Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency [PDF]

International Journal of Molecular Sciences, 2021
Margherita Doria, Daniela Angela Covino
exaly   +2 more sources

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal

Journal of Virus Eradication, 2016
T.M. Mota, G. Khoury, J.C. Jacobson, H.K. Lu, F. Wightman, d.e.r. Sluis, J.L. Anderson, P.U. Cameron, S.R. Lewin, D.F.J. Purcell, R.M. Van   +10 more
doaj   +2 more sources

Identification of a promising new class of latency reversing agents

Journal of Virus Eradication, 2017
A. Gramatica, W. Greene, R. Schwarzer, M. Montano, T. Packard, E. Herzig, Warner Greene   +6 more
doaj   +2 more sources

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents. [PDF]

Antimicrobial Agents and Chemotherapy, 2020
Indra Sarabia, Vicente Planelles, Ren Yanqin   +2 more
exaly   +2 more sources

G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells [PDF]

Cell Cycle, 2020
Stephen Dewhurst, Robert A Bambara, Sanjay B Maggirwar   +2 more
exaly   +2 more sources

Optimisation of Smac mimetics as HIV-1 latency reversing agents

Journal of Virus Eradication, 2019
L. Pache, P. Teriete, M.D. Marsden, A.M. Spivak, D. Heimann, A.J. Portillo, V. Planelles, J.A. Zack, N.D.P. Cosford, S.K. Chanda   +9 more
doaj   +2 more sources

Diversity of small molecule HIV-1 latency reversing agents identified in low- and high-throughput small molecule screens [PDF]

Medicinal Research Reviews, 2020
Ivan Sadowski, Pargol Hashemi
exaly   +2 more sources

Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. [PDF]

JCI Insight, 2018
The presence of a reservoir of latently infected cells in HIV-infected patients is a major barrier towards finding a cure. One active cure strategy is to find latency-reversing agents that induce viral reactivation, thus leading to immune cell recognition and elimination of latently infected cells, known as the shock-and-kill ...
Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A.   +10 more
europepmc   +4 more sources

Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. [PDF]

AIDS, 2020
Objective: While latently HIV-infected cells have been described in the blood, it is unclear whether a similar inducible reservoir exists in the gut, where most HIV-infected cells reside. Tissue-specific environments may contribute to differences in the mechanisms that govern latent HIV infection and amenability to reactivation.
Telwatte S, Kim P, Chen TH, Milush JM, Somsouk M, Deeks SG, Hunt PW, Wong JK, Yukl SA.   +8 more
europepmc   +6 more sources

Novel Latency Reversal Agents for HIV-1 Cure. [PDF]

Annu Rev Med, 2018
Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate ...
Spivak AM, Planelles V.
europepmc   +4 more sources